Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Norstella Introduces NorstellaLinQ, the Biopharma Industry's First Fully Integrated Data Asset


News provided by

Norstella

Oct 08, 2024, 10:00 ET

Share this article

Share toX

Share this article

Share toX

NorstellaLinQ integrates 74 billion connected data points, paving the way for breakthroughs in drug development and commercialization. This groundbreaking solution helps global pharmaceutical and life sciences companies bring lifesaving treatments to the patients who need them.

NEW YORK, Oct. 8, 2024 /PRNewswire-PRWeb/ -- Today, Norstella unveiled NorstellaLinQ, the biopharma industry's first and only fully integrated data asset combining both real-world data (RWD) — including open and closed claims, lab results and structured and unstructured electronic medical records (EMR) — with Norstella's proprietary forecasting, clinical, regulatory, payer, coverage and commercial intelligence data.

Bringing a new drug to market can cost billions of dollars, and the pathway to successfully developing treatments is long, expensive and complex. Norstella has a proven track record helping all of the major global pharmaceutical and life sciences companies navigate that path and bring lifesaving treatments to the patients who need them. With this groundbreaking solution, NorstellaLinQ is harnessing the power of its brands across the pharma pipeline — Citeline, Evaluate, MMIT, Panalgo, and The Dedham Group — for the first time. By bringing these brands together, Norstella is igniting the innovation needed by hundreds of companies to develop thousands of drugs and gain unparalleled access to the most comprehensive and connected dataset, driving sharper decision making and fueling powerful strategic initiatives.

In a recent Norstella survey of more than 100 pharma executives, nearly half of all respondents cited data integration and cleanliness as the number one hurdle to adopting new technologies. NorstellaLinQ solves these challenges by providing unparalleled data and insights to help clients strengthen their drug development strategy, accelerate and fine-tune decisions that drive next best actions, and precisely target the actions that drive success across the product lifecycle.

"NorstellaLinQ isn't just about bringing together data," said Mike Gallup, CEO of Norstella. "It's about creating the only solution in the market that links real-world patient data with the proprietary intelligence of Norstella's most trusted brands that have powered the pharmaceutical industry for decades. NorstellaLinQ provides our clients with a transformative capability to analyze, predict and act on insights that no other solution can deliver, truly smoothing the path from pipeline to patient."

A New Standard for Biopharma Data Integration

NorstellaLinQ integrates more than 74 billion data points — including the insights of 500,000 investigators, tens of thousands of clinical trials across 185 countries, hundreds of brand launches, and tens of thousands of forecasts — offering unparalleled context and clarity. It also identifies opportunities for portfolio planning, giving organizations a unique advantage in optimizing protocol design and investigator selection. Being more targeted with patient recruitment, fine-tuning product launch plans and, most importantly, identifying patient populations most in need of life-changing therapies quickly and accurately are all possible with NorstellaLinQ.

Unmatched Predictive Power

NorstellaLinQ uses the industry's richest multimodal real-world dataset, combining structured and unstructured data, harnessing the combined power of AI, large language models (LLMs) and machine learning on a robust cloud computing infrastructure with strong clinical acumen. Leveraging AI, tailored data visualizations and a generative AI analytics assistant trained on decisions made by countless industry experts, users now have the power to interrogate and explore the data that shapes their decisions with greater detail and better results.

NorstellaLinQ has tagged 1.5 million records to 55 custom and standard ontologies, from indication, dosage route, to mechanism of action and drug target, spanning the full lifecycle to help surface insights and recommendations from Norstella's data assets. In combination with Norstella's hundreds of MDs, epidemiologists, PhDs, pharmacists, RNs, technologists and data scientists, NorstellaLinQ can synthesize vast datasets to offer faster, more actionable insights, allowing companies to swiftly adjust strategies and capitalize on emerging opportunities.

Empowering Teams Across the Product Lifecycle

NorstellaLinQ supports multiple teams across the biopharma ecosystem:

  • Clinical operations teams can optimize protocol design, site and investigator selection.
  • Clinical trial teams can identify and recruit medically complex patients into treatment.
  • Brand teams can use predictive analytics to anticipate clinical symptoms triggering earlier diagnosis, drug switches, drug holidays and other patient dynamics to better anticipate patient behavior.
  • Pharma teams can analyze physician notes to understand the sentiment of clinical decision-making and understand if patient adherence is related to clinical outcomes or potential reimbursement challenges or denials.
  • Health Economics and Outcomes Research (HEOR) and epidemiology teams can scrutinize the largest patient-level dataset to generate evidence for improved patient outcomes and cost-benefit analysis.
  • Commercial teams can hyper target patients based on varying clinical criteria to reach physicians who are treating specific conditions.
  • Market access teams can track time to treatment in areas of restrictive behavior from insurers such as prior authorization, step therapy requirements, and medical exceptions and can advocate for more open access to speed time to therapy.

For more information on NorstellaLinQ, visit https://www.norstella.com/linq.

About Norstella

Our mission is simple: to smooth the path to lifesaving therapies for patients and providers. Norstella consists of prominent pharmaceutical solutions providers that have joined forces to offer a full range of consultancy services and solutions. Through its brands — Citeline, Evaluate, MMIT, Panalgo and The Dedham Group — Norstella supports biopharma companies in making smarter, faster decisions across the drug development and commercialization lifecycle. For more information visit Norstella and follow us on LinkedIn.

Media Contact

Jonathan Gelb, Norstella, 1 (646) 571-0120, [email protected], www.norstella.com

SOURCE Norstella

Modal title

Norstella logo
Norstella logo
Norstella logo

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.